


# **Data Sheet**

Product Name: TPI-1
Cat. No.: CS-6450
CAS No.: 79756-69-7
Molecular Formula: C12H6Cl2O2
Molecular Weight: 253.08

Target: Phosphatase

Pathway: Metabolic Enzyme/Protease

Solubility: DMSO: 50 mg/mL (197.57 mM; Need ultrasonic)



## **BIOLOGICAL ACTIVITY:**

TPI-1, also known as Tyrosine Phosphatase Inhibitor 1, is a **SHP-1** inhibitor; inhibits recombinant SHP-1 with an **IC**<sub>50</sub> of 40 nM. IC50 & Target: IC50: 40 nM (recombinant SHP-1)<sup>[1]</sup> **In Vitro**: SHP-1 has been implicated as a potential cancer therapeutic target. TPI-1 is effective starting at 10 ng/mL in increasing SHP-1 phospho-substrates pLck-pY394. TPI-1 selectively increases SHP-1 phospho-substrates (pLck-pY394, pZap70 and pSlp76) in Jurkat T cells but has little effects on pERK1/2 or pLck-pY505. TPI-1 induces mouse splenic-IFN $\gamma$ <sup>+</sup> cells and induces IFN $\gamma$ <sup>+</sup> cells in human peripheral blood<sup>[1]</sup>. **In Vivo**: TPI-1 inhibits the growth of B16 melanoma tumors in mice at a tolerated oral dose in a T cell-dependent manner but has little effects on B16 cell growth in culture. TPI-1 thus also increases pLck-pY394 and IFN $\gamma$ <sup>+</sup> cells in mice. TPI-1 also inhibits B16 tumor growth and prolongs tumor mice survival as a tolerated s.c. agent<sup>[1]</sup>.

# PROTOCOL (Extracted from published papers and Only for reference)

Animal Administration: TPI-1 is prepared in PBS.<sup>[1]</sup>Mice: For in vivo induction of pLck-pY394 and IFN $\gamma$ + cells in mice, C57BL/6J mice are treated with PBS or TPI-1 (1 or 3 mg/kg, s.c.) for 4 days. Spleens are harvested one hour post-treatment on day 4 and processed into splenocytes, which are used for assessing pLck-pY394 levels by SDS-PAGE/Western blotting and for quantification of IFN $\gamma$ + cells by ELISPOT assays. Mice are also treated with TPI-1 (10 mg/kg, daily, s.c.) to evaluate the toxicity of the compounds in vivo<sup>[1]</sup>.

#### References:

[1]. Kundu S, et al. Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents. J Immunol. 2010 Jun 1;184(11):6529-36.

#### **CAIndexNames**:

2,5-Cyclohexadiene-1,4-dione, 2-(2,5-dichlorophenyl)-

### **SMILES:**

 $\mathsf{CIC1}\!=\!\mathsf{CC}(\mathsf{C2}\!=\!\mathsf{CC}(\mathsf{C}\!=\!\mathsf{CC2}\!=\!\mathsf{O})\!=\!\mathsf{O})\!=\!\mathsf{C}(\mathsf{CI})\mathsf{C}\!=\!\mathsf{C1}$ 

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 1 of 1 www.ChemScene.com